Anaplastic Thyroid Carcinoma

  • Abut Kebudi
  • Uğur Deveci
  • Bülent Çitgez


Anaplastic thyroid carcinoma (ATC) is a relatively uncommon highly malignant tumor originating from the follicular cells of the thyroid gland having a poor prognosis. It accounts for 2–5% of all thyroid carcinomas, and patients typically present with a rapidly growing anterior neck mass with aggressive symptoms. A 66-year-old male presented with dyspnea, neck pain, and voice changes. Ultrasonographic neck examination demonstrated an enlarged thyroid gland and substernal extension of the right thyroid lobe. Fine needle aspiration (FNA) from the thyroid nodule biopsy showed benign cytology. Because of symptomatic disease and radiologic malignancy doubt, operation has been done. Histopathologic examination with frozen section demonstrated anaplastic thyroid carcinoma. After total thyroidectomy, the patient is discharged. The patient died 20 days after the start of systemic treatment because of septic multiorgan failure derived from bronchopneumonic lung infection. In the evaluation of sudden growing neck masses in elderly patients, anaplastic thyroid cancer should be considered as a differential diagnosis, even if the needle biopsy is normal.


Anaplastic Biopsy Carcinoma Thyroid 


  1. 1.
    Ursino S, Fiorica F, Stafenelli A, Pedriali M, Colosimo C, Cocuzza P, et al. Anaplastic thyroid cancer: a case report of a long term survival patient and review of literature data. Eur Rev Med Pharmacol Sci. 2014;18:1368–72.PubMedGoogle Scholar
  2. 2.
    Hundahl SA, Cady B, Cunningham MP, Mazzaferri E, McKee RF, Rosai J, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German thyroid cancer study group. An American College of Surgeons Commission on cancer patient care evaluation study. Cancer. 2000;89:202–17.CrossRefGoogle Scholar
  3. 3.
    Xing JC, Bishop JA, Mathioudakis N, Agrawal N, Tufano RP. A large nonmetastatic anaplastic thyroid cancer with complete thyroidal confinement. Case Rep Med. 2011;2011:1–4. Scholar
  4. 4.
    Smallridge RJ, Copland JA. Anaplastic thyroid carcinoma: pathogenesis and emerging therapies. Clin Oncol. 2010;22:486–7.CrossRefGoogle Scholar
  5. 5.
    Goffredo P, Thomas SM, Adam MA, Sosa JA, Roman SA. Impact of timeliness of resection and thyroidectomy margin status on survival for patients with anaplastic thyroid cancer: an analysis of 335 cases. Ann Surg Oncol. 2015;22:4166–74. Scholar
  6. 6.
    Brown RF, Ducic Y. Aggressive surgical resection of anaplastic thyroid carcinoma may provide long-term survival in selected patients. Otolaryngol Head Neck Surg. 2013;148:564–71.CrossRefGoogle Scholar
  7. 7.
    Us-Krasovec M, Golouh R, Auersperg M, Besic N, Ruparcic-Oblak L. Anaplastic thyroid carcinoma in fine needle aspirates. Acta Cytol. 1996;40:953–8.CrossRefGoogle Scholar
  8. 8.
    Chambers AJ, Pasieka JL. Poorly differentiated and undifferentiated thyroid cancer. In: Johnathan H, William BI, Chung-Yau L, editors. Endocrine surgery principles and practice. London: Springer; 2009. p. 121–36.Google Scholar
  9. 9.
    Michael Tuttle R, Sherman EJ, Cooper DS, Ross DS, Mulder JE. Uptodate Knowledgebase. Massachusetts, US; 2017. Accessed Mar 2017.
  10. 10.
    Ruan DT, Clark OH. Anaplastic thyroid carcinoma, metastases to the thyroid gland, and thyroid lymphoma. In: Morita SY, Dackiw APB, Zeiger MA, editors. Endocrine surgery. New York: McGraw-Hill; 2010. p. 110–24.Google Scholar
  11. 11.
    Smallridge RC, Ain KB, Asa SL, Bible KC, Brierley JD, Burman KD, et al. American Thyroid Association guidelines for Management of Patients with anaplastic thyroid cancer. Thyroid. 2012;22:1104–39. Scholar
  12. 12.
    De Crevoisier R, Baudin E, Bachelot A, Leboulleux S, Travagli JP, Caillou B, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60:1137–43. Scholar
  13. 13.
    Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer. 1985;56:2155–216.CrossRefGoogle Scholar
  14. 14.
    Voigt W, Kegel T, Weiss M, Mueller T, Simon H, Schmoll HJ, et al. Potential activity of paclitaxel, vinorelbine and gemcitabine in anaplastic thyroid carcinoma. J Cancer Res Clin Oncol. 2005;131:585–90. Scholar
  15. 15.
    Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726–36. Scholar
  16. 16.
    So K, Smith RE, Davis SR. Radiotherapy in anaplastic thyroid carcinoma: an Australian experience. J Med Imaging Radiat Oncol. 2017;61:279–87.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Abut Kebudi
    • 1
  • Uğur Deveci
    • 2
  • Bülent Çitgez
    • 3
  1. 1.Division of Breast and Endocrine Surgery, General Surgery DepartmentOkan UniversityIstanbulTurkey
  2. 2.Division of Breast and Endocrine Surgery, General Surgery DepartmentMaltepe UniversityIstanbulTurkey
  3. 3.Division of Breast and Endocrine Surgery, General Surgery DepartmentŞişli Hamidiye Etfal Training and Research HospitalIstanbulTurkey

Personalised recommendations